[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prof. Dr. med. Ingo Eitel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":146},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,64,84,103,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100390290","the-german-italian-spanish-takotsubo-geist-registry-100390290",false,"NCT04361994","The GErman Italian Spanish Takotsubo (GEIST) Registry","GEIST","Inclusion Criteria:\n\n* Patients with Takotsubo syndrome\n\nExclusion Criteria:\n\n* Non","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","6 Months","OBSERVATIONAL","GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography \u002Fechocardiography \u002F coronary angiography parameters, treatment and medication), in-hospital course and complications and short-\u002Flong-term outcome are collected prospectively and retrospectively to increase the understanding of the disease.",[25],"Takotsubo Syndrome","RECRUITING","2025-12-18",{"date":29,"type":30},"2025-12-26","ACTUAL",{"date":32,"type":30},"2015-04",{"date":34,"type":20},"2035-12",{"name":36,"class":37},"Prof. Dr. med. Ingo Eitel","OTHER",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100577889","phase-3-sglt2-inhibition-for-cardiovascular-endpoint-reduction-in-hypertension-100577889","NCT06804161","SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension","SGLT2-HYPE","Inclusion Criteria:\n\n1. Age ≥60 years\n2. Systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension.\n3. A history of at least one CV event (myocardial infarction\\* or stroke\\*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack)\n\nor\n\nThe presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; LDL-cholesterol \\> 4,0 mmol\u002Fl, Age ≥ 75 years, ESC HeartScore \\> 15%, BMI \\> 32 kg\u002Fm2)\n\n\\*excluding patients with myocardial infarction or stroke within preceding 3 months\n\nExclusion Criteria:- Known secondary cause of hypertension\n\n* Myocardial infarction or stroke within the previous 3 months\n* Symptomatic heart failure (including HFrEF, HFmEF, HFpEF)\n* History of Diabetes mellitus\n* History of ketoacidosis\n* Hepatic impairment (aspartate transaminase \\[AST\\] or alanine transaminase \\[ALT\\] \\>3x the upper limit of normal \\[ULN\\])\n* eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m2 (CKD-EPICr 2021 formula) at Visit 1\n* Receiving therapy with an SGLT2i within 8 weeks prior to randomization or previous intolerance to an SGLT2i\n* Participation in another clinical study with an investigational product during the last month prior to enrolment\n* Known allergy or hypersensitivity to SGLT2i\n* Women who are pregnant, nursing, or who plan to become pregnant while in the trial\n* Any medical condition - outside the renal and CV disease area - with a life expectancy of less than 2 years based on investigator's clinical judgement\n* Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma)\n* Inability to give informed consent","60 Years",{"count":48,"type":20},3000,"INTERVENTIONAL",[51],"PHASE3","Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.",[54],"Atrial Hypertension","2025-12-15",{"date":57,"type":30},"2025-12-22",{"date":59,"type":30},"2025-12-10",{"date":61,"type":20},"2032-05-30",{"name":36,"class":37},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":63},"100591185","interventional-structural-registry---luebeck-100591185","NCT06977139","Interventional Structural Registry - LuEbeck","INSTYLE","Inclusion Criteria:\n\n* Structural heart disease\n\nExclusion Criteria:\n\n* Patients without consent\u002Finformation\n* Age ≤ 18 years",{"count":72,"type":20},2000,"The aim of the registry is to investigate the effect of catheter-assisted procedures in the context of structural heart disease on clinical morbidity and mortality. Furthermore, the long-term prognosis of patients after a catheter-based procedure is to be evaluated.\n\nIn particular, the following parameters will be documented and the following questions discussed:\n\n* Underlying and concomitant diseases of these patients\n* Evaluation of the methods in relation to the respective disease\n* Safety - acute and long-term\n* Effectiveness - periprocedural, hospital and long-term course\n* Concomitant therapies",[75],"Structural Heart Disease","2025-05-08",{"date":78,"type":30},"2025-05-18",{"date":80,"type":30},"2021-09-11",{"date":82,"type":20},"2035-01-01",{"name":36,"class":37},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":63},"100577888","myval-transcatheter-heart-valve-system---prospective-german-multicenter-registry-100577888","NCT06804148","MYVAL Transcatheter Heart Valve System - Prospective German Multicenter Registry","German MYVAL S","Inclusion Criteria:\n\n* Patient is going to be treated with Myval THV\n* Age ≥ 18 years\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Patients with hyper sensitivity or allergy to aspirin, heparin, clopidogrel, ticlopidine, cobalt, nickel, chromium, molybdenum or any contrast media.\n* Patients in whom anti-platelet and\u002For anticoagulant therapy are contra-indicated.\n* Any condition, which in the Investigator's opinion, would preclude safe participation of patient in the registry",{"count":72,"type":20},"Rational of the Myval THV - Prospective German Multicenter Registry is to evaluate the performance of this relatively new but very promising TAVR valve in a consecutive real-word, all-comers registry and to assess the long-term durability and efficacy of the Myval THV.",[94],"Aortic Valve Stenosis","2025-01-27",{"date":97,"type":30},"2025-02-03",{"date":99,"type":30},"2025-01-01",{"date":101,"type":20},"2030-12-30",{"name":36,"class":37},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":49,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":63},"100454951","left-atrial-appendage-closure-in-patients-with-non-valvular-atrial-fibrillation-and-end-stage-chronic-kidney-disease-100454951","NCT05204212","Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","Prospective, Randomized, Controlled, Unblinded, International, Multicentre, Parallel Two Group Trial of Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage","LAA-KIDNEY","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to give informed consent\n* Documented NVAF (paroxysmal, persistent, or permanent)\n* CHA2DS2VASc risk score ≥2\n* Chronic kidney disease KDOQI stage 5 (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2) with or without hemodialysis\n\nExclusion Criteria:\n\n* Absolute contraindication to aspirin and\u002For clopidogrel\n* Comorbidities other than AF requiring chronic (N)OAC therapy e.g. mechanical heart valve prosthesis\n* Present LAA thrombus\n* Mobile aortic atheroma\n* Age ≤18 years\n* Patients presenting with pregnancy\n* Patients without informed consent\n* Participation in another trial\n* Expected life expectancy \\\u003C2 years",{"count":112,"type":20},430,[114],"NA","In the proposed event driven trial, LAA closure devices will be compared in a 1:1 randomization to best medical care in AF patients at high risk of stroke and bleeding with ESKD. The trial will allow the use of the CE marked and clinically used LAA device Amplatzer Cardiac Plug and\u002For Amulet and all approved medical therapies in AF patients with ESKD including vitamin-K antagonists (VKA), NOACs as well as antiplatelet agents or no anticoagulation in excessive bleeding risk.",[117],"Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent","2024-05-10",{"date":120,"type":30},"2024-05-13",{"date":122,"type":30},"2022-03-28",{"date":124,"type":20},"2028-01-14",{"name":36,"class":37},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":49,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":63},"100405388","cardiac-magnetic-resonance-guidance-of-implantable-cardioverter-defibrillator-implantation-in-non-ischemic-dilated-cardiomyopathy-100405388","NCT04558723","Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy","Randomized Controlled, Multi-centre Trial of Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy","CMR-ICD","Inclusion Criteria:\n\n* NIDCM (idiopathic or familial)\\*\n* LVEF ≤35% and presence of fibrosis on CMR\n* Diagnostic CMR scan\n* Age ≥18 years\n* Written informed consent\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* ICM \\[previous myocardial infarction, previous percutaneous coronary intervention\\]\n* Other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathies \\[e.g. cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis and iron overload cardiomyopathy\\], left ventricular non-compaction cardiomyopathy, reversible cardiomyopathies \\[Takotsubo syndrrome, peripartum cardiomyopathy, chemotherapy induced cardiomyopathy\\].\n* Myocarditis\n* Contraindication for CMR at study entry (including severe claustrophobia, pacemaker or ICD, metallic cerebral or intracranial implants, known allergy to gadolinium)\n* Severe renal insufficiency (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Current pacemaker or defibrillator in situ\n* Current indication for device therapy (e.g. secondary prophylaxis after aborted SCD)\n* Renal impairment defined as an eGFR \\\u003C30 milliliters\n* Age \\\u003C18 years\n* Patients presenting with pregnancy\n* Patients without informed consent\n* Participation in another randomized trial\n* Life expectancy \\\u003C2 years",{"count":135,"type":20},760,[114],"Patients with diagnostic CMR images for assessment of LGE\u002Ffibrosis and evidence\u002Fpresence of non-ischaemic myocardial fibrosis\u002Fscar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.",[139],"Non-ischemic Dilated Cardiomyopathy",{"date":120,"type":30},{"date":142,"type":30},"2021-01-14",{"date":144,"type":20},"2027-11",{"name":36,"class":37},""]